Business Wire

CA-MITOQ

13.4.2022 13:07:05 CEST | Business Wire | Press release

Share
MitoQ Unveils Empowering New Branding That Champions Emerging Cell Health Category and Reflects Unique Science Leadership Position

MitoQ Ltd. , a New Zealand-based cell health company that developed a world-first sub-cellular targeted antioxidant which directly combats cell stress, today announced a complete transformation of the brand with a fresh new design, updated visual language and sustainable packaging. MitoQ is the developer of the unique, next-generation cell health molecule with the same name, that is scientifically shown to penetrate deep within the cells to reduce cell stress. By supporting the body’s primary energy source – the mitochondria -- MitoQ is able to target cell stress and improve energy, increase exercise recovery and resilience and promote healthy aging. The patented, powerful cell technology and active ingredients in MitoQ will remain the same, but the rebrand elevates the company’s purpose, its differentiated position in the wider category and role as a pioneer of cell health with a new look and feel, including new packaging, visual communications and brand messaging.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220413005266/en/

“MitoQ is more than a supplement – it is biodesigned differently to be extraordinarily effective and safe, it’s backed by decades of independent global research and supported by clinical trials and hundreds of peer reviewed scientific publications,” said Mahara Inglis, chief executive officer of MitoQ. “Rebranding is one of the steps we are taking to raise awareness of the importance of cells for overall wellbeing and draw attention to our unique technology. All the elements in our new branding and packaging are designed to reflect the unique position we hold -- not only in the health and wellness space -- but in the emerging cellular health category which we have been pioneering for decades, and also the positive impact we make on our customers’ lives. MitoQ helps all individuals – whether they are managing a health condition, juggling busy days at work or as a parent, or those just wanting to age ‘better’ by reducing cell stress. We wanted our new brand to visually depict our proprietary science and appeal to all individuals who want to improve their health, starting at the smallest level: their cells. The new branding captures the essence of MitoQ’s purpose, unique mechanism of action and the positive user experience and we’re thrilled to introduce it to the world.”

The MitoQ rebrand was undertaken to revitalize the brand position, establish a clear point of differentiation in the category and ensure all packaging was sustainable to prevent inefficiencies that may contribute to environmental harm. To help inform the strategy and execution for the rebrand, MitoQ partnered with UK-based brand transformation consultancy, Born Ugly . Through a collaborative, agile process, Born Ugly was able to support MitoQ to more effectively define the brand’s identity, vision and purpose, including business and consumer insight generation, strategic plan development, brand definition, creation and design and brand activation. At the heart of the work was the shift of the brand’s purpose from supporting consumers to ‘power through life’ to ‘empower their purpose’ through products and experiences. The approach needed to overcome cultural differences and reasons for taking MitoQ in its key markets – primarily the U.S. and China. A unifying mindset was identified that could connect the different audiences rooted in a deep human truth that when people feel their best, they can have the most positive influence on those around them.

MitoQ’s new visual articulation was rooted in the idea that small changes can have a significant and positive ripple effect on overall health, life, and the broader community. The ‘power of small’ was the idea that influenced everything within MitoQ’s new brand, including cell-inspired packaging, imagery, illustration, animation, language, and a logo that articulates a cell universe optimized at the heart by MitoQ’s small molecule. Essentially the brand proposition is that small can be big.

“Today marks a significant milestone in the history and forward growth of our company. MitoQ is not only a reputable, innovative company pioneering new technology in the emerging cellular health category, but we are a supportive and loyal community of health-minded people who are committed to making a positive impact in the world around us,” said John Marshall, chief marketing officer at MitoQ. “This project was an intense and rewarding labor of love for the entire commercial organization. We are incredibly grateful to our strategic partners, external and internal advisors, the MitoQ team and the millions of global customers who helped provide thoughtful, invaluable feedback and perspective that led to the development of this refreshed, dynamic brand. We look forward to the commercial rollout and sharing this new brand experience with our customers across multiple global regions in the coming months.”

MitoQ is a multi-patented, advanced antioxidant molecule that delivers targeted support to the cells’ mitochondria. The mitochondria provide approximately 90% of the energy the human body needs to function. As a by-product of this energy production process, the mitochondria also produce free radicals, and with age (coupled with other external and environmental stressors), the body loses its natural resistance to diffuse them. MitoQ is bio-designed to be absorbed deep inside of the cells where it can neutralize free radicals to combat cell stress, resulting in more energy, faster exercise recovery, immune support, deeper focus and overall optimized health. For more information, visit www.mitoQ.com .

MitoQ is available globally via the brand website (www.mitoQ.com ), and Amazon.com.

About MitoQ

MitoQ is a New Zealand cellular health company that invented an advanced molecule which is clinically proven to target cells for better health. Created at the University of Otago in the 1990s, MitoQ’s unique ingredient is available in a range of cellular products designed to power the health and ambitions of every body. MitoQ’s potential benefits to health have been the subject of 12 clinical trials and over 600 independent published research papers by the likes of Harvard Medical School, UCLA and the University of Cambridge, and it holds 60 patents globally. For more information about the company and its products, visit www.mitoQ.com

Link:

ClickThru

Social Media:

https://www.facebook.com/MitoQ/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release

STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD

Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release

Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to

Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria

Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm

SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release

SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye